UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

 

 

 

FORM 8-K

  

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 26, 2017

 

Fortress Biotech, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

001-35366

20-5157386 

(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

2 Gansevoort Street, 9th Floor

New York, New York 10014

(Address of Principal Executive Offices)

 

(781) 652-4500

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 ☐ Written communications pursuant to Rule 425 under the Securities Act.
 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 ☐ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
 ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

  

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

  (b) Departure of Certain Officers.

 

On June 26, 2017, Lucy Lu, M.D. resigned as Chief Financial Officer of Fortress Biotech, Inc. (the “Company”).

 

(c) Appointment of Certain Officers.

 

On June 26, 2017, Robyn Hunter, 55, was appointed as the Company’s Chief Financial Officer.

 

Ms. Hunter has more than 30 years of financial and operational experience in an array of industries. Since June 2011, Ms. Hunter has served as the Company’s Vice President and Corporate Controller where she has implemented financial and operational processes, procedures and policies to facilitate the Company’s execution of its growth strategy. From January 2006 to May 2011, Ms. Hunter served as Senior Vice President and Chief Financial Officer of Schochet Associates. From August 2004 to January 2006, Ms. Hunter served as the Corporate Controller for Indevus Pharmaceuticals. From 1990 to 2004, Ms. Hunter held several positions from Accounting Manager to Vice President and Treasurer of The Stackpole Corporation. Ms. Hunter holds a Bachelor of Arts degree in Economics from Union College in Schenectady New York.

 

No family relationships exist between Ms. Hunter and any of the Company’s directors or other executive officers. There are no arrangements between Ms. Hunter and any other person pursuant to which Ms. Hunter was selected as an officer, nor are there any transactions to which the Company is or was a participant and in which Ms. Hunter has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Fortress Biotech, Inc.  

 

(Registrant)

 

Date: June 30, 2017

 
     
 

By:

/s/ Lindsay A. Rosenwald, M.D.  
 

Lindsay A. Rosenwald, M.D.  
 

Chairman, President and Chief Executive Officer